103 related articles for article (PubMed ID: 18640164)
1. Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine.
Rodriguez PC; Gonzalez I; Gonzalez A; Avellanet J; Lopez A; Perez R; Lage A; Montero E
Vaccine; 2008 Aug; 26(36):4647-54. PubMed ID: 18640164
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine.
Montero E; Valdes M; Avellanet J; Lopez A; Perez R; Lage A
Vaccine; 2009 Apr; 27(16):2230-9. PubMed ID: 19428837
[TBL] [Abstract][Full Text] [Related]
3. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK
Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates.
Morera Y; Bequet-Romero M; Ayala M; Velazco JC; Pérez PP; Alba JS; Ancizar J; Rodríguez M; Cosme K; Gavilondo JV
Vaccine; 2010 Apr; 28(19):3453-61. PubMed ID: 20197134
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
6. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.
Gonzalez G; Crombet T; Torres F; Catala M; Alfonso L; Osorio M; Neninger E; Garcia B; Mulet A; Perez R; Lage R
Ann Oncol; 2003 Mar; 14(3):461-6. PubMed ID: 12598354
[TBL] [Abstract][Full Text] [Related]
8. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
[TBL] [Abstract][Full Text] [Related]
9. Effect of P64k presensitization on its efficacy as an immunological carrier in mice.
González S; Caballero E; Silva R; Pajón R
Biochem Biophys Res Commun; 2001 Mar; 282(2):376-9. PubMed ID: 11401468
[TBL] [Abstract][Full Text] [Related]
10. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
Aguilar FF; Barranco JJ; Fuentes EB; Aguilera LC; Sáez YL; Santana MD; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
Vaccine; 2012 Oct; 30(46):6595-9. PubMed ID: 22921738
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease.
Rodriguez G; Gonzalez G; Crombet T; Lage A
Expert Rev Respir Med; 2011 Jun; 5(3):337-42. PubMed ID: 21702656
[TBL] [Abstract][Full Text] [Related]
12. Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine.
Ramírez BS; Alpízar YA; Fernández DR; Hidalgo GG; Capote AR; Rodríguez RP; Fernández LE
Vaccine; 2008 Sep; 26(38):4918-26. PubMed ID: 18672015
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.
Junco JA; Peschke P; Zuna I; Ehemann V; Fuentes F; Bover E; Pimentel E; Basulto R; Reyes O; Calzada L; Castro MD; Arteaga N; López Y; Garay H; Hernández H; Bringas R; Guillén GE
Vaccine; 2007 Dec; 25(50):8460-8. PubMed ID: 18022737
[TBL] [Abstract][Full Text] [Related]
14. Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine.
Johansson J; Hellman L
Vaccine; 2007 Feb; 25(9):1676-82. PubMed ID: 17150285
[TBL] [Abstract][Full Text] [Related]
15. Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.
Valdes-Zayas A; Gonzalez Z; Mulens V; Vega AM; Perez K; Lorenzo-Luaces P; Rubio MC; Estevez A; Curbelo I; Fernandez LE; Crombet T; Mazorra Z
J Immunother; 2017 Oct; 40(8):289-301. PubMed ID: 28604556
[TBL] [Abstract][Full Text] [Related]
16. Effect of an EGF-cancer vaccine on wound healing and inflammation models.
Casacó A; Díaz Y; Ledón N; Merino N; Vadés O; Garcia G; Garcia B; González G; Pérez R
J Surg Res; 2004 Nov; 122(1):130-4. PubMed ID: 15522325
[TBL] [Abstract][Full Text] [Related]
17. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits.
Halassy B; Vdović V; Habjanec L; Balija ML; Gebauer B; Sabioncello A; Santek T; Tomasić J
Vaccine; 2007 Apr; 25(17):3475-81. PubMed ID: 17239503
[TBL] [Abstract][Full Text] [Related]
19. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
[TBL] [Abstract][Full Text] [Related]
20. Human Cripto-1 as a target for a cancer vaccine: WO2008040759.
Bianco C; Salomon DS
Expert Opin Ther Pat; 2009 Feb; 19(2):141-4. PubMed ID: 19441915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
